Tyrosine kinase inhibitorFDA-approvedSecond-line
Binimetinib
How it works
Blocks MEK, a protein involved in cell growth and division, which can help slow the growth of cancer cells.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
In clinical trials, around 50% of patients with BRAF V600E or V600K mutation achieved an objective response, with a median progression-free survival of approximately 2 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing New Cancer Treatment Combination in Advanced Tumors | Breast Cancer | phase-1 | — | Source → |
| Testing Binimetinib for Relapsed/Refractory Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Encorafenib Plus Binimetinib for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Testing Binimetinib and Imatinib for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Combining Futibatinib and Binimetinib in Advanced Cancer Treatment | Lung Cancer | phase-1 | — | Source → |
| Testing Treatments for Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing Binimetinib and Encorafenib for Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Study of Encorafenib and Binimetinib in Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Advanced Melanoma Treatment Trial Evaluates Combination of Three Study Medicines | Melanoma | phase-3 | — | Source → |
| Testing Binimetinib Plus Belinostat for Metastatic Uveal Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Palbociclib and Binimetinib in RAS-Mutant Cancers | Pancreatic Cancer | phase-2 | — | Source → |
| Combining Metformin and Binimetinib May Help Fight Melanoma | Melanoma | lab-study | — | Source → |
| MEK Inhibitor Shows Modest Effectiveness in Advanced Melanoma | Melanoma | observational | The disease control rate was 60.0%. | Source → |
| Study of Encorafenib and Binimetinib for BRAF Mutant Melanoma with Brain Metastasis | Melanoma | phase-2 | Treatment with encorafenib plus binimetinib demonstrated a brain metastasis response rate of over 60%. | Source → |
| New Treatment Option for Lung Cancer Patients with V600E Mutation | Lung Cancer | phase-2 | Encorafenib plus binimetinib achieved the primary endpoint of objective response rate by independent review committee. | Source → |
| Researchers Identify Potential Biomarkers for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | In patients treated with binimetinib, the response rate was 41% in those with MAPK pathway alterations, and 13% in those without. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.